Subutex Pill: A Clinician’s Guide to Buprenorphine Without Naloxone, Its Appearance, Uses, Dosage, Side Effects, and When It Is Prescribed Instead of Suboxone

What Subutex is, what the pill looks like in its various strengths, how it differs from Suboxone, the specific clinical situations in which Subutex is preferred including pregnancy and known naloxone allergy, the standard dosing protocols for opioid use disorder treatment, the side effects to expect, and what families and patients should understand about this form of medication-assisted treatment.

Clinically reviewed by Dr. Ponlawat Pitsuwan, Physician and Addiction Medicine Specialist, Phuket Island Rehab.

Subutex is the brand name for sublingual buprenorphine tablets without naloxone. The pill is most commonly white, oval-shaped, and supplied in 2 milligram and 8 milligram strengths, with the 2 milligram tablet usually marked with the number 54 411 on one side and the 8 milligram tablet marked 54 375. The medication is a partial mu-opioid receptor agonist used primarily for the treatment of opioid use disorder and for pain management. Subutex differs from Suboxone in that Suboxone contains both buprenorphine and naloxone in a 4 to 1 ratio, while Subutex contains buprenorphine alone. The naloxone in Suboxone is included as an abuse deterrent that produces precipitated withdrawal if the tablet is injected, but is inactive when the tablet is dissolved under the tongue as directed. Subutex is preferred over Suboxone in several specific clinical situations including pregnancy, known naloxone allergy, severe liver impairment, and during initial induction in some protocols. The original Subutex brand was discontinued in the United States in 2011 but generic sublingual buprenorphine tablets continue to be available under various manufacturer names. The medication is highly effective for opioid use disorder treatment, with strong evidence for reducing illicit opioid use, reducing overdose deaths, and supporting long-term recovery when combined with behavioural treatment.

What Subutex is and its place in opioid use disorder treatment

Subutex is the original brand name for sublingual buprenorphine tablets that contain buprenorphine as the only active ingredient, without the naloxone that is included in Suboxone. The medication was approved by the U.S. Food and Drug Administration in 2002 alongside Suboxone for the office-based treatment of opioid use disorder, ending the era when methadone was the only available medication-assisted treatment for opioid dependence and that required daily attendance at federally regulated clinics. The brand Subutex was discontinued by manufacturer Reckitt Benckiser in 2011 in the United States, but generic sublingual buprenorphine tablets remain available and are still commonly referred to as Subutex in clinical practice and patient conversation.

Buprenorphine itself is a synthetic opioid derived from thebaine, with a chemical structure that produces a unique pharmacological profile distinct from morphine, oxycodone, hydrocodone, methadone, or other full mu-opioid receptor agonists. The medication acts as a partial agonist at the mu-opioid receptor, meaning that it binds to the receptor and produces an effect but the maximum effect produced is limited even at higher doses. This ceiling effect is one of the key safety features of buprenorphine: respiratory depression, which is the main cause of opioid overdose death, plateaus at higher doses rather than continuing to increase linearly the way it does with full agonists.

The medication is classified as a Schedule III controlled substance in the United States, a less restrictive schedule than the Schedule II classification of methadone and the full agonist opioids. The lower scheduling reflects the lower abuse potential associated with the ceiling effect on respiratory depression and the reduced euphoric effect compared with full agonists. Despite the lower scheduling, buprenorphine remains a controlled substance with meaningful abuse potential and is prescribed under federal regulations that previously required X-waivered providers, with these restrictions removed in 2023 to expand access to treatment.

What the Subutex pill looks like

The Subutex pill in its various generic forms has a distinctive appearance that allows recognition by patients, families, and clinicians. The 2 milligram tablet is most commonly white, oval, and approximately 7 to 9 millimetres in length, with the imprint 54 411 on one side and a score line on the other. The 8 milligram tablet has similar appearance but is larger, approximately 9 to 11 millimetres in length, with the imprint 54 375. The exact appearance varies somewhat between manufacturers, with different generic versions having slightly different shapes, sizes, and imprint markings. Common manufacturers of generic sublingual buprenorphine tablets include Roxane, Aurobindo, Hi-Tech Pharmacal, Mylan, and Sun Pharma.

The tablets are designed for sublingual dissolution, meaning they are placed under the tongue and allowed to dissolve over 5 to 10 minutes rather than being swallowed or chewed. The sublingual route is necessary because buprenorphine has very poor oral bioavailability; if the tablet were swallowed, the medication would be largely destroyed by first-pass metabolism in the liver before reaching the systemic circulation. The sublingual route bypasses the first pass and allows absorption directly through the rich blood supply of the floor of the mouth. The tablets have a faintly sweet taste that some patients find unpleasant initially but most adjust to over time.

Several alternative formulations of buprenorphine are also available and may be encountered alongside or instead of Subutex tablets. Suboxone is the same buprenorphine with naloxone added, available as sublingual films or tablets in 2/0.5, 4/1, 8/2, and 12/3 milligram strengths. Sublocade is a monthly subcutaneous injection of buprenorphine that provides sustained release over 30 days and is used for established patients who are stable on sublingual treatment. Brixadi is another long-acting buprenorphine formulation. Probuphine was a buprenorphine implant that was withdrawn from the U.S. market in 2020. Belbuca is a buccal film formulation used primarily for chronic pain rather than opioid use disorder.

How buprenorphine works in the brain

The mechanism of action of buprenorphine has several features that combine to produce its unique clinical profile. The medication binds with very high affinity to the mu-opioid receptor, meaning it occupies the receptor strongly and displaces other opioids that may be present. This high binding affinity is the basis for the precipitated withdrawal that can occur if buprenorphine is taken too soon after a recent full-agonist opioid: the buprenorphine displaces the full agonist from the receptors and the resulting net reduction in receptor activation produces acute withdrawal.

Once bound, buprenorphine produces only partial activation of the mu-opioid receptor, approximately 40 to 50 percent of the maximal effect that a full agonist would produce. The partial activation is sufficient to prevent withdrawal in patients with opioid dependence, to reduce or eliminate craving, and to provide pain relief in chronic pain patients. The partial activation is also why the medication produces a ceiling effect on respiratory depression and on euphoric effects, contributing to the safety profile relative to full agonists.

Buprenorphine also acts as an antagonist at the kappa-opioid receptor, which may contribute to the antidepressant and anti-anxiety effects that some patients describe with the medication. The kappa antagonism is being investigated as a potential mechanism for using buprenorphine in treatment-resistant depression in research settings. The medication’s elimination half-life is long, approximately 24 to 60 hours depending on the patient, which allows once-daily dosing in most patients and provides sustained occupancy of the mu-opioid receptors between doses.

The clinical effects of an oral or sublingual dose develop over 30 to 60 minutes and peak at one to four hours. The duration of effect at therapeutic doses is 24 to 48 hours, with some patients on stable maintenance therapy able to dose every other day or even less frequently. The sustained receptor occupancy means that the patient does not experience the dose-response peaks and troughs that characterise short-acting opioids, which is one reason that buprenorphine is associated with stable mood and function rather than the up-and-down pattern of full agonists.

When Subutex is preferred over Suboxone

The choice between Subutex (buprenorphine alone) and Suboxone (buprenorphine with naloxone) depends on several specific clinical considerations. For the majority of patients, Suboxone is the standard first-line treatment because the included naloxone provides an abuse deterrent that reduces the risk of intravenous misuse of the tablet, with no clinically meaningful effect when the tablet is dissolved under the tongue as directed. Subutex is reserved for situations in which the naloxone component is contraindicated or undesirable.

Pregnancy is the most well-established indication for Subutex over Suboxone. The naloxone in Suboxone, while inactive when taken sublingually as directed in adults, has uncertain effects on fetal development and on the neonate after birth. Most clinical guidelines including those from the American College of Obstetricians and Gynecologists and the American Society of Addiction Medicine recommend Subutex (buprenorphine alone) for pregnant patients with opioid use disorder, with transition to Suboxone after delivery if clinically appropriate. The treatment of opioid use disorder during pregnancy with buprenorphine is associated with substantially better outcomes than untreated opioid use disorder, including reduced rates of neonatal abstinence syndrome and improved maternal and infant health.

Known naloxone allergy or sensitivity is a second indication for Subutex. True allergic reactions to naloxone are rare but do occur and are a clear contraindication to Suboxone. Some patients also describe non-allergic adverse effects from the naloxone component, including nausea, dysphoria, or anxiety that resolves when switched to buprenorphine without naloxone. In these patients, Subutex provides equivalent therapeutic effect without the adverse experience.

Severe hepatic impairment is a third indication. Naloxone is metabolised in the liver and patients with severe hepatic impairment may accumulate naloxone with possible adverse effects. The buprenorphine itself is also metabolised in the liver and dose adjustment is appropriate in significant liver disease, but the additional naloxone exposure can be avoided by using Subutex in these patients. Mild to moderate liver impairment typically does not require switching from Suboxone.

Some induction protocols favour Subutex during the initial induction period for stability reasons, with transition to Suboxone after the patient is stable on buprenorphine. The approach is variable across clinicians and not universal, but reflects a preference for the simpler pharmacology of buprenorphine alone during the initial titration. After stable induction, transition to Suboxone provides ongoing maintenance treatment with the abuse deterrent benefit.

Dosage and how Subutex is taken

The standard adult dose range for buprenorphine in the treatment of opioid use disorder is 8 to 24 milligrams daily, with most patients stabilising on 16 milligrams. The induction phase typically begins with 2 to 4 milligrams as a test dose to assess tolerance, with additional 2 to 4 milligram doses given every one to two hours as needed to a total day-one dose of 8 to 12 milligrams. The dose is then titrated upward over the next several days based on craving suppression, withdrawal coverage, and side effect tolerability. Most patients reach a stable maintenance dose within one to two weeks of induction.

Taking the medication correctly is important for absorption and effect. The tablet should be placed under the tongue and allowed to dissolve completely without swallowing, talking, or drinking for at least five minutes. Patients who swallow the tablet receive only a small fraction of the active dose because of poor oral bioavailability. Patients who chew the tablet damage the dissolution profile and may experience inadequate effect. Patients with dry mouth may benefit from drinking a small amount of water before the dose to moisten the sublingual area, but should not drink during or immediately after the dissolution.

The medication is typically dosed once daily, taken at a consistent time of day. Twice daily dosing is appropriate for some patients during induction or when stable doses do not provide 24-hour coverage. The dose can be split across the day if needed but the long half-life of buprenorphine means that once daily dosing is sufficient for most patients on maintenance therapy. Missed doses should be taken as soon as remembered unless it is close to the time for the next dose, in which case the missed dose should be skipped.

Patients who have been on opioids should be in mild to moderate withdrawal before the first dose of buprenorphine to avoid precipitated withdrawal. The standard guidance is to wait 12 to 24 hours after the last dose of short-acting opioids (heroin, oxycodone, hydrocodone) and 24 to 72 hours after methadone before starting buprenorphine. The Clinical Opiate Withdrawal Scale (COWS) is used to assess the level of withdrawal and ensure adequate time has elapsed. Patients in active intoxication from full agonist opioids should not receive buprenorphine because of the high risk of precipitated withdrawal.

Side effects and what to expect

The side effects of buprenorphine are similar to those of other opioids but generally milder and more tolerable. The most common side effects in the first weeks of treatment include constipation, headache, nausea, sweating, insomnia, and a small initial reduction in libido or sexual function. Constipation is the most persistent side effect and may continue throughout treatment, requiring ongoing management with stool softeners, osmotic laxatives, or in severe cases peripherally-acting opioid antagonists such as methylnaltrexone or naloxegol. Most other side effects diminish over the first few weeks of stable treatment.

Dental problems have emerged as a significant concern with sublingual buprenorphine in recent years. The FDA issued a safety communication in 2022 noting reports of dental decay, tooth fracture, dental abscesses, and other dental problems in patients taking sublingual buprenorphine. The mechanism is thought to involve the prolonged contact of the slightly acidic dissolving tablet with the teeth and gums, combined with the reduced salivary flow that opioids can produce. Patients on sublingual buprenorphine should rinse their mouth with water after each dose (without swallowing for at least 30 minutes), maintain good oral hygiene with twice-daily brushing and flossing, and see a dentist regularly. The dental concern is one factor in the trend toward depot buprenorphine formulations including Sublocade and Brixadi for established patients.

Hepatotoxicity has been reported with buprenorphine, particularly in patients with pre-existing liver disease including chronic hepatitis B and C. Liver function should be checked at baseline and periodically during treatment, with attention to any rising transaminases or new symptoms of liver dysfunction. The risk is small in patients without pre-existing liver disease. Allergic reactions are uncommon but can occur and include rash, swelling, and rarely anaphylaxis.

Combining buprenorphine with benzodiazepines, alcohol, or other central nervous system depressants substantially increases the risk of respiratory depression, even though the buprenorphine itself has a ceiling effect on respiratory depression. The FDA strengthened warnings about this combination in 2017. Patients should not drink heavily, should not take benzodiazepines without medical guidance, and should be aware that the combination with sleep medications, sedating antihistamines, or other CNS depressants requires medical assessment.

Effectiveness of buprenorphine treatment

The evidence base for buprenorphine in the treatment of opioid use disorder is extensive and consistent. Meta-analyses and systematic reviews show substantial reductions in illicit opioid use, reductions in overdose deaths, improvements in social and occupational functioning, reductions in criminal activity, and improvements in HIV and hepatitis C transmission risk in patients receiving buprenorphine compared with placebo, no treatment, or detoxification alone. The effect sizes are large and clinically meaningful, and the medication is one of the most effective treatments in addiction medicine.

The combination of buprenorphine with addiction-focused counselling produces somewhat better outcomes than buprenorphine alone, but buprenorphine without counselling still produces substantial improvement compared with no treatment. This finding has supported the expansion of buprenorphine prescribing in primary care settings where counselling resources may be limited but where the medication itself can be provided. The 2023 removal of the X-waiver requirement in the United States substantially expanded the number of clinicians eligible to prescribe buprenorphine and is expected to improve access to treatment.

Duration of treatment is an important clinical question. Current evidence supports indefinite maintenance treatment for most patients with opioid use disorder, with discontinuation being associated with high rates of relapse and overdose. Patients who do discontinue should do so with a gradual taper over weeks to months under medical supervision, with strong outpatient support and recovery activities in place. Many patients remain on buprenorphine for years, with stable function and quality of life that they could not achieve without the medication.

Subutex versus methadone for opioid use disorder

Buprenorphine and methadone are the two FDA-approved opioid agonist treatments for opioid use disorder. The choice between them depends on several factors. Methadone has a longer evidence base and produces somewhat better outcomes for patients with severe opioid use disorder, but it must be dispensed through federally regulated opioid treatment programs that typically require daily attendance during the initial phase. Buprenorphine can be prescribed by appropriately qualified physicians in office-based settings, making it substantially more accessible for patients who cannot attend a methadone clinic daily.

The safety profile of buprenorphine, with its ceiling effect on respiratory depression, makes it generally safer than methadone for patients without close clinical monitoring. The ceiling effect also makes accidental overdose less likely. However, methadone remains the more effective treatment for selected patients including those with very high opioid tolerance, those who have failed buprenorphine treatment, and those who do well in the structured environment of a methadone clinic. The two medications are complementary rather than competitive, and many programs offer both.

Switching between methadone and buprenorphine is more complex than switching between full-agonist opioids because of the partial agonist nature of buprenorphine and the long half-life of methadone. Transition from methadone to buprenorphine requires waiting until methadone blood levels are low enough to avoid precipitated withdrawal, typically 24 to 72 hours after the last methadone dose with the methadone dose reduced to 30 milligrams or lower beforehand. Transition from buprenorphine to methadone is more straightforward but still requires careful planning.

Misuse and diversion of Subutex

Diversion and misuse of buprenorphine occur and are a recognised problem in addiction medicine. The pattern includes patients receiving prescriptions and selling or sharing the medication, patients obtaining buprenorphine through illegitimate sources for self-management of opioid use disorder without formal treatment, and recreational use of the medication by people who do not have opioid dependence. The motivation for diverted use is often the patient’s desire to manage their own opioid withdrawal between supplies of illicit opioids, rather than purely recreational use, and this pattern is sometimes called self-medication of opioid use disorder.

The recreational use of buprenorphine produces euphoria in people without opioid dependence, particularly at higher doses, but the effect is generally milder than that of full-agonist opioids. The abuse potential is lower than that of heroin, oxycodone, hydrocodone, or methadone, which is the basis for the Schedule III classification. Intravenous misuse of buprenorphine is the most clinically concerning pattern and is the abuse pathway that the naloxone in Suboxone is designed to deter. Subutex without naloxone is more susceptible to intravenous misuse than Suboxone, which is one reason Suboxone has become the more commonly prescribed formulation.

Despite these concerns, the public health benefit of expanding buprenorphine access substantially outweighs the harm from diversion. People who use diverted buprenorphine to manage their opioid use disorder, even outside of formal treatment, have lower overdose death rates than people using only illicit opioids. The harm reduction perspective accepts some level of diversion as a price worth paying for the broader benefits of buprenorphine access, while continuing to work toward better integration of diverted users into formal treatment.

When opioid use disorder coexists with alcohol use disorder

Alcohol use disorder, which is the clinical term for what most people call alcoholism, frequently coexists with opioid use disorder and complicates buprenorphine treatment. Heavy alcohol use can produce respiratory depression in combination with buprenorphine, can interfere with the social and behavioural recovery that buprenorphine supports, and can be a continuing source of harm even after the opioid use is controlled. Patients on buprenorphine who continue to drink heavily often do not achieve the full benefit of the treatment.

Integrated treatment of co-occurring alcohol use disorder and opioid use disorder is the standard approach. Medical detoxification under supervision is often needed for the alcohol component, with the buprenorphine continued throughout. Medications for alcohol use disorder including naltrexone and acamprosate can be used alongside buprenorphine, though naltrexone interactions need careful management because both medications act at opioid receptors. Phuket Island Rehab provides residential addiction medicine treatment for international patients with co-occurring opioid use disorder and alcohol use disorder, including continuation of buprenorphine treatment throughout the residential stay.

Summary

Subutex is sublingual buprenorphine without naloxone, available as generic tablets in 2 milligram and 8 milligram strengths with characteristic imprints and appearance. The medication is a partial mu-opioid receptor agonist used primarily for the treatment of opioid use disorder and for chronic pain management. The difference from Suboxone is the absence of the naloxone component, which makes Subutex preferred in pregnancy, in patients with known naloxone allergy, in severe hepatic impairment, and in some induction protocols. The medication is highly effective for opioid use disorder treatment, with strong evidence for reducing illicit opioid use, preventing overdose deaths, and supporting long-term recovery. Side effects are similar to other opioids but generally milder, with dental problems emerging as a specific concern with sublingual buprenorphine. The combination with benzodiazepines, alcohol, or other CNS depressants is dangerous. As Dr. Ponlawat Pitsuwan summarises, “Subutex remains an important option in the toolkit even though most patients now receive Suboxone. For pregnant patients, for those with naloxone allergy, and for the small number of patients who do better on buprenorphine alone, the option matters. The therapeutic effect of the two is essentially identical at standard sublingual doses and the choice can be tailored to the individual clinical situation.”

Frequently asked questions

What is Subutex used for?

Subutex is used primarily for the treatment of opioid use disorder and for chronic pain management. The medication suppresses opioid withdrawal symptoms, reduces craving, prevents the euphoria of additional opioid use through receptor occupancy, and supports stable function in patients who would otherwise be using illicit opioids. The 2002 FDA approval enabled office-based treatment of opioid use disorder for the first time.

What does a Subutex pill look like?

Generic sublingual buprenorphine tablets are most commonly white, oval, and supplied in 2 milligram and 8 milligram strengths. The 2 milligram tablet is approximately 7 to 9 millimetres in length with the imprint 54 411, and the 8 milligram tablet is approximately 9 to 11 millimetres in length with the imprint 54 375. Exact appearance varies between manufacturers.

What is the difference between Subutex and Suboxone?

Subutex contains buprenorphine alone, while Suboxone contains buprenorphine plus naloxone in a 4 to 1 ratio. The naloxone in Suboxone is included as an abuse deterrent that produces precipitated withdrawal if the tablet is injected, but is inactive when the tablet is dissolved under the tongue as directed. At standard sublingual dosing, the therapeutic effect of the two is essentially identical.

Is Subutex still available in the United States?

The original Subutex brand was discontinued by manufacturer Reckitt Benckiser in 2011 in the United States, but generic sublingual buprenorphine tablets continue to be available under various manufacturer names. The medication is still commonly referred to as Subutex in clinical practice and patient conversation even when the generic form is being prescribed.

How long does Subutex stay in your system?

The elimination half-life of buprenorphine is approximately 24 to 60 hours, allowing once-daily dosing in most patients. The medication is detectable in standard urine drug tests for 3 to 7 days after the last dose, longer with chronic use. Specialised buprenorphine urine testing is required because routine opioid panels typically do not detect buprenorphine.

Is Subutex addictive?

Buprenorphine is a controlled substance with abuse potential and produces physical dependence with regular use, but the abuse liability is lower than that of full-agonist opioids because of the ceiling effect on euphoria and respiratory depression. Stopping buprenorphine after long-term use produces withdrawal symptoms that are typically milder and longer-lasting than withdrawal from full agonists. The medication is most safely used as part of comprehensive treatment with eventual structured taper or indefinite maintenance based on individual clinical assessment.

Sources

• U.S. Food and Drug Administration (FDA). Subutex (buprenorphine) prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020732s006lbl.pdf
• U.S. Food and Drug Administration (FDA). FDA warns about dental problems with buprenorphine medicines dissolved in the mouth to treat opioid use disorder and pain. https://www.fda.gov/drugs/drug-safety-and-availability
• Substance Abuse and Mental Health Services Administration (SAMHSA). Medications for Opioid Use Disorder: TIP 63. https://store.samhsa.gov/product/TIP-63
• American College of Obstetricians and Gynecologists. Opioid Use and Opioid Use Disorder in Pregnancy. Committee Opinion No. 711. 2017. https://www.acog.org/clinical/clinical-guidance/committee-opinion
• Mattick RP, Breen C, Kimber J, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database of Systematic Reviews. 2014;(2):CD002207. https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD002207.pub4/full
• National Institute on Drug Abuse (NIDA). Medications to Treat Opioid Use Disorder Research Report. https://nida.nih.gov/publications/research-reports/medications-to-treat-opioid-addiction
• American Society of Addiction Medicine (ASAM). National Practice Guideline for the Treatment of Opioid Use Disorder. 2020. https://www.asam.org/quality-care/clinical-guidelines/national-practice-guideline

Subutex, buprenorphine, Suboxone, naloxone, buprenorphine-naloxone, sublingual tablet, sublingual film, Sublocade, Brixadi, Probuphine, Belbuca, opioid use disorder, OUD, partial mu-opioid agonist, partial agonist, full agonist, mu-opioid receptor, kappa-opioid receptor, ceiling effect, respiratory depression, precipitated withdrawal, Clinical Opiate Withdrawal Scale, COWS, Reckitt Benckiser, Schedule III controlled substance, DEA, FDA, X-waiver, DATA 2000, MAT, medication-assisted treatment, methadone, heroin, oxycodone, hydrocodone, fentanyl, half-life, pharmacokinetics, sublingual administration, bioavailability, first-pass metabolism, induction, maintenance, taper, withdrawal symptoms, opioid withdrawal, constipation, hepatotoxicity, dental problems, tooth decay, benzodiazepines, alcohol use disorder, CNS depressants, neonatal abstinence syndrome, NAS, neonatal opioid withdrawal syndrome, NOWS, pregnancy, naloxone allergy, hepatic impairment, liver disease, hepatitis B, hepatitis C, naltrexone, Vivitrol, acamprosate, methylnaltrexone, naloxegol, FDA, SAMHSA, NIDA, NHS, American Society of Addiction Medicine, ASAM, American College of Obstetricians and Gynecologists, ACOG, residential rehab, Phuket Island Rehab, addiction medicine, harm reduction, diversion.